"MIRACLE" FAT-MELTING DRUG OZEMPIC HAS been linked in a study to a series of rare but potentially fatal psychiatric episodes, scientists have warned.
The injectable prescription drug was developed to manage blood sugar levels in patients with Type 2 diabetes, but it has gained popularity and gone viral on social media due to one sought-after side effect: weight loss.
Ozempic is based on a naturally occurring human hormone called glucagon-like peptide 1, which plays an important role in regulating appetite and blood sugar levels. Its active ingredient is a molecule called semaglutide, which mimics the structure of this GLP-1 hormone and activates its receptors.
In doing so, semaglutide induces feelings of fullness while delaying the emptying of our stomach, making us less hungry and therefore less likely to overeat.
Semaglutide is also used in Ozempic's sister drug, Wegovy, which has been approved by the FDA for chronic weight management. Between the start of 2020 and the end of 2022, prescriptions of GLP-1 mimic medications like semaglutide increased by 300 percent across the U.S., according to health care analytics firm Trilliant Health.
The drug has since been endorsed by celebrities and influencers, with #ozempic reaching over 1.4 billion views on TikTok. However, when used as a weight-loss drug, semaglutide has been shown to have some uncomfortable side effects.
Most studies into these have focused on gut problems, but a new study, published in the International Journal of Clinical Pharmacy, has highlighted a concerning association between semaglutide and adverse psychiatric events, including depression, anxiety and suicidal thoughts. Pharmaceutical manufacturer Novo Nordisk, which produces Ozempic and Wegovy, cited the FDA saying that no evidence was found regarding suicidal thoughts or actions caused by these medicines.
Bu hikaye Newsweek US dergisinin March 22, 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Newsweek US dergisinin March 22, 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
AMERICA'S BEST LOYALTY PROGRAMS 2025
LOYALTY PROGRAMS HAVE BECOME A CORNERSTONE of the modern shopping experience, offering perks and rewards designed to keep customers returning for more.
Winning the Global Game
The U.S. holds more cards than China. Whether we keep our strategic advantage depends on how we play our hand
Solar Power
Scientists' creation of a record-breaking \"artificial sun\" brings nuclear fusion energy a step closer to being a commercial reality
Trump vs. Deep State
The president and his efficiency chief Elon Musk have brought in a wave of policies affecting federal employees' jobs. Government workers spoke to Newsweek about the impact
MAD ABOUT THE GIRL
AS RENÉE ZELLWEGER REPRISES THE ICONIC CHARACTER, BRIDGET JONES' CREATOR - AND MILLIONS OF FANS, COULDN'T BE HAPPIER
Armed and Dangerous
A Ukrainian colonel reveals how North Korean soldiers compared with their Russian allies
Patrick Gibson
WHEN YOU TAKE ON A ROLE THAT SOMEBODY ELSE MADE FAMOUS, IT'S not easy.
The AI Will See You Now
A light-hearted study into artificial intelligence's ability to perform cognitive tasks has raised questions around the roles of AI and doctors in health care
Jasmin Savoy Brown
SHOWTIME'S YELLOWJACKETS IS REALLY TWO shows in one.
BIOTECH: Blood, Sweat and Tears
Nine years in the making, Truvian's quick tabletop blood test promises to deliver where Theranos famously couldn't
